130284-35-4

Basic information

• Product Name: 2-phenyl-pent-4-en-1-ol
• CAS NO: 130284-35-4
• Molecular Weight: 162.232
• Mol File: 130284-35-4.mol
• Article Data: 26

Chemical Properties

• CAS DataBase Reference: 2-phenyl-pent-4-en-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-phenyl-pent-4-en-1-ol(130284-35-4)
• EPA Substance Registry System: 2-phenyl-pent-4-en-1-ol(130284-35-4)

Safety Data

• Hazardous Substances Data: 130284-35-4(Hazardous Substances Data)

Upstream product

• 96-09-3 styrene oxide 
• 7393-43-3 tetraallyl tin 
• 130004-39-6 allyltitanium triphenoxide 
• 106-95-6 allyl bromide 
• 1730-25-2 allylmagnesium bromide 
• 1575-70-8 2-phenyl-pent-4-enoic acid 
• 103-82-2 phenylacetic acid 
• 1802-55-7 diallylzinc 
• 34522-48-0 2-phenyl-4-pentenenamide 
• 24401-36-3 2-phenyl-4-penten-1-al 
• 101-97-3 Ethyl 2-phenylethanoate 
• 14815-74-8 ethyl 2-phenylpent-4-enoate 
• 101-41-7 benzeneacetic acid methyl ester 
• 1471-03-0 allyl propyl ether 

Downstream Products

• 1076-66-0 3-phenyl-1,5-hexadiene 
• 24401-36-3 2-phenyl-4-penten-1-al 
• 134692-37-8 2-iodomethyl-4-phenyltetrahydrofuran 
• 134692-46-9 2-phenylpent-4-enyl acetate 
• 431-03-8 dimethylglyoxal 
• 182194-86-1 2-phenyl-4-penten-1-yl p-toluenesulfonate 
• 79109-00-5 1-(2-phenyl-pent-4-enyl)-1H-[1,2,4]triazole 
• 413603-62-0 [1-(2-phenyl-pent-4-enyl)-1H-imidazol-4-yl]-acetonitrile 
• 413603-63-1 4-nitro-1-(2-phenyl-pent-4-enyl)-1H-imidazole 
• 413603-28-8 4-phenyl-1-(2-phenyl-pent-4-enyl)-1H-imidazole 
• 413603-64-2 4,5-dichloro-1-(2-phenyl-pent-4-enyl)-1H-imidazole 
• 413603-68-6 5-phenyl-1-(2-phenyl-pent-4-enyl)-1H-tetrazole 
• 413603-67-5 5-phenyl-2-(2-phenyl-pent-4-enyl)-2H-tetrazole 

Relevant articles and documents

Carbometalations of simple alkenes with allyldibromoborane.

[formula: see text] The allylboration of alkenes with allyldibromoborane is described. Utilizing an improved methodology for the synthesis of allyldibromoborane, 1,3-dienes, styrene, and even isolated alkenes could be carbometalated in high yield regio- a

Radical Aryl Migration from Boron to Carbon

Radical aryl migration reactions represent a unique type of organic transformations that involve the intramolecular migration of an aryl group from a carbon or heteroatom to a C- or heteroatom-centered radical through a spirocyclic intermediate. Various elements, including N, O, Si, P, S, Sn, Ge, and Se, have been reported to participate in radical aryl migrations. However, radical aryl migration from a boron center has not been reported to date. In this communication, radical 1,5-aryl migration from boron to carbon in aryl boronate complexes is presented. C-radicals readily generated through radical addition onto alkenyl aryl boronate complexes are shown to engage in 1,5-aryl migration reactions to provide 4-aryl-alkylboronic esters. As boronate complexes can be generatedin situby the reaction of alkenylboronic acid esters with aryl lithium reagents, the aryl moiety is readily varied, providing access to a series of arylated products starting from the same alkenylboronic acid ester via divergent chemistry. Reactions proceed with high diastereoselectivity under mild conditions, and also the analogous 1,4-aryl shifts are feasible. The suggested mechanism is supported by DFT calculations.

Highly Enantioselective Catalytic Kinetic Resolution of α-Branched Aldehydes through Formal Cycloaddition with Homophthalic Anhydrides

A new catalytic methodology was developed to promote an efficient one-pot kinetic resolution of racemic aldehydes with selectivity (s*) of up to 91 (99:1 d.r., >99 % ee) in a cycloaddition reaction with enolizable anhydrides to afford dihydroisocoumarin products (a core prevalent in natural products and molecules of medicinal interest) containing three contiguous stereocentres.

COMPOUNDS THAT INHIBIT MCL-1 PROTEIN

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.